title: Health-related quality of life in I-125 prostate brachytherapy patients treated with and without volume-reducing hormone therapy: results of a short-term prospective study.
abstract: OBJECTIVE
  This study describes the differences in short-term effects of health-related quality of life (HRQOL) in I-125 prostate brachytherapy patients who were treated with and without volume-reducing hormone therapy.
  
  
  METHODS
  Prostate cancer patients (N = 312) filled out questionnaires on HRQOL (European Organization of Research and Treatment of Cancer Quality of Life Questionnaire [EORTC-QLQ]-C30 and EORTC-QLQ-PR25) before treatment and 6 weeks and 3 months after treatment. HRQOL was compared between the two groups: Patients who were receiving brachytherapy (n = 233) and patients who were receiving brachytherapy with volume-reducing hormone therapy (n = 79). Duration of androgen ablation was 9 months, starting 3 months before I-125 implantation.
  
  
  RESULTS
  After treatment, patients reported significant and clinically relevant decreased scores on the following subscales: Global health status, role functioning, social functioning, pain, insomnia, bowel symptoms and functioning, and treatment-related functions, regardless of the therapy they received. Results showed that prostate cancer patients receiving brachytherapy with volume-reducing hormone therapy also experienced lower treatment-related functions and lower sexual function. Significant time by treatment interaction effects were found for treatment-related functions. The subscale treatment-related functions was the only scale that showed a difference over time, between treatments, and time by treatment.
  
  
  CONCLUSIONS
  The differences in HRQOL between brachytherapy and brachytherapy with volume-reducing hormone therapy are small; they both decrease HRQOL and increase treatment-related problems. A long-term prospective study on long-term effects on HRQOL is needed to obtain a more comprehensive view of the consequences of a specific treatment modality over time. Our results can help to identify the problems patients face after brachytherapy with or without hormone therapy; these problems deserve additional attention during the period of recovery.
authors.affiliation: CoRPS-Center of Research on Psychology in Somatic Diseases, Tilburg University, Tilburg, The Netherlands.
authors.forename: Floortje
authors.initials: F
authors.lastname: Mols
authors.forename: Pascal
authors.initials: P
authors.lastname: Stijns
authors.forename: Bram
authors.initials: B
authors.lastname: Dankaart
authors.forename: Saskia
authors.initials: S
authors.lastname: Houterman
authors.forename: Ad
authors.initials: A
authors.lastname: Vingerhoets
authors.forename: Ad
authors.initials: A
authors.lastname: Hendrikx
mesh_terms: D000328:Adult; D000368:Aged; D000728:Androgens / Q000627:therapeutic use*; D001918:Brachytherapy; D003710:Demography; D006262:Health; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D011788:Quality of Life; D011795:Surveys and Questionnaires; D013997:Time Factors
chemical_list: D000728:Androgens